Skip to content

Spark Therapeutics launches gene therapy programmes with $50M investment

Spark Therapeutics, a new company spun out of the Children’s Hospital of Philadelphia (CHOP), has announced the launch of two gene therapy programmes following a $50M capital commitment from the hospital. The company, led by CEO & President, Jeffrey D. Marrazzo, includes gene therapy pioneers Jean Bennett, M.D., Ph.D., J. Fraser Wright, Ph.D. and Katherine A. High, M.D., among its founders. The company aims to progress two late stage programmes – a Phase III study for inherited blindness causes by RPE65 mutations and a Phase I/II study for haemophilia B.